
Cellular transformation is accompanied by many cellular changes, including uncontrolled proliferation, loss of the differentiated cell morphology, and invasion of the extracellular matrix. Degradation of the extracellular matrix is a key component of tumor cell invasion into surrounding tissues. Matrix metalloproteinases (MMPs) are a class of proteases secreted by tumor cells, degrading the proteins of the extracellular matrix and allowing metastasis. Drug inhibitors of MMPs are one strategy to control cancer and block metastasis. In searching for genes that reverse the rounded morphology of transformed cells in culture, RECK was identified (reversion-inducing, cysteine-rich protein with Kazal motifs). RECK is a membrane-anchored inhibitor of matrix metalloproteinases, inhibiting MMP-2, MMP-9 and MT1-MMP. The processing of MMPs to their active form occurs at the plasma membrane, making the localization of RECK at the membrane a key to its potent activity as an inhibitor of MMP activity. Soluble secreted MMP inhibitors have also been identified, TIMPs, which appear to be less active at inhibiting MMPs and even perhaps to be essential for MMP maturation. The inhibition of MMPs by RECK inhibits invasion of tissues, metastasis and tumor angiogenesis, and is essential for normal development. In addition to playing a role in tissue invasion in cancer, the activity of MMPs in angiogenesis, inflammation, and development is regulated by inhibitors such as RECK and TIMPs. RECK expression is inhibited by ras, suggesting one component by which ras induces transformation. High levels of RECK expression in tumors is correlated with cancer patient survival and overexpression of RECK may offer a therapeutic strategy for the control of cancer.
Contributor:
REFERENCES: Furumoto K. et al. (2001) RECK gene expression in hepatocellular carcinoma, Correlation with invasion-related clinicopathological factors and its clinical significance. Hepatology, 33, 189-195. Oh, J. et al. (2001) The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107, 789-800 Sasahara R.M., Takahashi C. and Noda M. (1999) Involvement of the Sp1 site in ras-mediated downregulation of the RECK metastasis suppressor gene. Biochem. Biophys. Res. Commun., 264, 668-675. Skiles JW, Gonnella NC, Jeng AY. (2001) The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 8(4), 425-74 Takahashi, C et al. (1998) Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Nat. Acad. Sci. 95, 13221-13226 Vu, T.H. and Werb, Z. (2000) Matrix metalloproteinases, effectors of development and normal physiology. Genes Dev. 14, 2123-2133. Weaver VM (2002) Membrane-associated MMP regulators: novel cell adhesion tumor suppressor proteins? Dev. Cell. 2(1), 6-7
2026年5月29日,第二十三屆中國國際科學儀器及實驗室裝備展覽會(CISILE2026)現場,分析測試百科網舉辦了2026年度ANTOP獎頒獎盛典。北京精微高博儀器有限公司憑借兩款產品獲雙獎。Mat......
蛋白質作為構成人體組織器官的支架和主要物質,在人體生命活動中起著重要作用。蛋白質的相互作用能產生許多效應,如形成特異底物作用通道、生成新的結合位點、失活、作用底物專一性和動力學變化等,細胞的代謝、信號......
2021年9月9日,無錫臻和生物科技有限公司(以下簡稱“臻和科技”)與美國VyantBio公司簽署TissueofOrigin?(以下簡稱“TOO?”)全球權益和ZL轉讓協議,全資收購這款唯一獲FDA......
2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同時撤回了中國學者49篇文章。從2019年開始,Journalo......
磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......
2018年12月6日,來自圣迭戈的消息——Illumina公司(納斯達克股票代碼:ILMN)今天宣布推出新型高密度基因分型芯片Infinium?GlobalDiversityArray。這款芯片設計源......
賽默飛世爾科技,世界領先的服務商,于2008年1月29日宣布將在其BioWorks?軟件中整合入MatrixScience’sMascot?蛋白鑒定搜索技術。源于華盛頓大學的SEQUEST?搜索算法(......
SDS-PAGE異常電泳現象及分析SDS-PAGEHallofShame.pdf 很不錯的東東~~推薦下~......
Preparationofdenaturing6%polyacrylamidegelsformicrosatelliteanalysis(alsoforSSAP,high-resolutionIRAP......